Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2141.1987.tb04160.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synergistic effect of inulin hydrogels on multi-strain probiotics for prevention of ionizing radiation-induced injury.
Int J Biol Macromol
December 2024
School of Pharmacy, Anhui Medical University, Hefei 230032, China; Beijing Institute of Radiation Medicine, Beijing 100850, China. Electronic address:
Prebiotics and probiotics are applied against multiple diseases including ionizing radiation-induced injury but their functions are not revealed enough. Here, we used a prebiotic, inulin hydrogels (IGs) to load multi-strain probiotics (MSPs) for protecting them from the gastrointestinal environment and improving their colonization in the gut; more importantly, they showed the synergistic effect against ionizing radiation-induced injury. Probiotics were embedded in a great number of channels of the IGs and used IGs as food.
View Article and Find Full Text PDFPrediction of Viable CD34 Count in Harvested Product by Peripheral Blood Hematopoietic Progenitor Count of Automated Hematology Analyzer Undergoing Hematopoietic Stem Cell Transplantation.
J Blood Med
August 2024
Department of Hematology, Hospital Ampang, Ampang Jaya, Selangor, Malaysia.
Introduction: The CD34+ hematopoietic cell count was used to define cell harvest goals. Successful peripheral blood stem cell transplantation depends on infusion of an appropriate number of HPCs to achieve rapid and durable hematologic recovery.
Purpose: In this study, we evaluated the use of the Hematopoietic Progenitor Cell count program on the Sysmex XN-3000 hematology analyzer as an effective parameter for enumerating CD34+ cells.
High variability in short and long-term recovery kinetic of blood cell count and blood chemistry in a partial body irradiation mouse model.
Int J Radiat Biol
March 2024
Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Purpose: In the aftermath of a nuclear disaster or accident, survivors will suffer from radiation-induced normal tissue damage. Recovery after radiation exposure is dictated by several factors, one of which is degree of shielding at time of exposure. This study aims to characterize the short and late term changes in kinetics and magnitude of pancytopenia and blood chemistry in a model of heterogeneous radiation exposure, or partial body irradiation (PBI), compared to whole body irradiation (WBI).
View Article and Find Full Text PDFQ-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.
Trials
September 2023
Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Article Synopsis
- Approximately 50% of older patients with acute myeloid leukemia (AML) do not achieve complete remission after traditional chemotherapy, and alternatives like higher doses of cytarabine combined with mitoxantrone have low success rates, especially for those with the unfavorable FLT3-ITD marker.* -
- This study investigates the efficacy of quizartinib, a selective FLT3 inhibitor, combined with a chemotherapy regimen (HAM) in a randomized phase II trial, assessing outcomes such as complete remission rate compared to historical controls.* -
- The trial employs a novel matched threshold crossing approach to bolster the reliability of results by comparing the current treatment outcomes with data from previous similar studies, aiming to improve the understanding of
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.
Lancet Haematol
August 2023
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China; Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China. Electronic address:
Background: Our open-label, multicentre, randomised, phase 3 trial showed that sorafenib maintenance after haematopoietic stem-cell transplantation (HSCT) improved overall survival and reduced relapse for patients with FLT3 internal tandem duplication (FLT3-ITD) acute myeloid leukaemia undergoing allogeneic HSCT. Here, we present a post-hoc analysis on the 5-year follow-up data of this trial.
Methods: This phase 3 trial, done in seven hospitals in China, included patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic HSCT, who were aged 18-60 years, had an Eastern Cooperative Oncology Group performance status of 0-2, had composite complete remission before and after transplantation, and had haematopoietic recovery within 60 days after transplantation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!